GlassScriptPhysician profile
Elizabeth M Naylor
NPI 1376702761
$2,681.27
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $83.04 · 2021: $534 · 2022: $680 · 2023: $424 · 2024: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $376.15 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $330.24 | 2021-2024 | Tremfya |
| Ucb, INC. | $268.58 | 2020-2024 | Bimzelx, Cimzia |
| Abbvie INC. | $213.73 | 2019-2024 | |
| Lilly USA, LLC | $184.91 | 2021-2023 | Olumiant, Taltz |
| Prugen, INC. Pharmaceuticals | $175.00 | 2021 | |
| Leo Pharma INC. | $157.17 | 2022-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $155.13 | 2019-2023 | Winlevi, Absorica Ld, Ilumya |
| Janssen Scientific Affairs, LLC | $148.70 | 2022 | |
| Stemline Therapeutics INC. | $128.47 | 2021 | |
| Genzyme Corporation | $106.27 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $69.34 | 2019-2024 | Dupixent |
| Pfizer INC. | $59.02 | 2020-2023 | |
| Incyte Corporation | $55.14 | 2022-2024 | Opzelura |
| Merz North America, INC. | $42.70 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.67 | 2020-2022 | |
| Biofrontera INC. | $37.75 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.07 | 2024 | Cabtreo |
| Mayne Pharma Commercial LLC | $20.49 | 2019 | |
| Almirall LLC | $17.89 | 2023 | Seysara |
| Merck Sharp & Dohme LLC | $15.40 | 2019 | |
| Mission Pharmacal Company | $14.35 | 2019 | |
| Vyne Pharmaceuticals INC. | $14.29 | 2020 | |
| Genentech USA, INC. | $13.17 | 2019 | |
| Galderma Laboratories, L.P. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Naylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.